Dermatomyositis Clinical Trial
Official title:
A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T Cells (CABA-201) in Subjects With Active Idiopathic Inflammatory Myopathy
RESET-Myositis: Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects with Active Idiopathic Inflammatory Myopathy
Idiopathic inflammatory myopathies (IIMs, or myositis) are a group of rare autoimmune diseases characterized by inflammation and muscle weakness. Though the cause of IIM is not well understood, some subtypes of IIM, including dermatomyositis (DM), anti-synthetase syndrome (ASyS), and immune-mediated necrotizing myopathy (IMNM), are thought to involve B cells that cause the body to attack different tissues in the body. This study is being conducted to evaluate the safety and efficacy of an investigational cell therapy, CABA-201, that can be given to patients with DM, ASyS, and IMNM who have active disease. A single dose of CABA-201 in combination with cyclophosphamide (CY) and fludarabine (FLU) will be evaluated. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05833711 -
Study Evaluating Efficacy and Safety of Froniglutide (PF1801) in Patients With Idiopathic Inflammatory Myopathy
|
Phase 2 | |
| Not yet recruiting |
NCT06284954 -
A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis
|
Phase 2 | |
| Completed |
NCT01906372 -
Acthar in Treatment of Refractory Dermatomyositis and Polymyositis
|
Phase 2 | |
| Completed |
NCT01813617 -
Outcome in Patients With Recent Onset Polymyositis and Dermatomyositis
|
N/A | |
| Completed |
NCT01165008 -
Anakinra in Myositis
|
Phase 2/Phase 3 | |
| Completed |
NCT00004357 -
Absorption of Corticosteroids in Children With Juvenile Dermatomyositis
|
Phase 2 | |
| Recruiting |
NCT05832034 -
Add-on Intravenous Immunoglobulins in Early Myositis
|
Phase 2 | |
| Recruiting |
NCT05979441 -
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy
|
Phase 3 | |
| Not yet recruiting |
NCT05027152 -
Muscle Function and Effects of Repetitive Task Training in Patients With Inflammatory Myopaties
|
N/A | |
| Active, not recruiting |
NCT04723303 -
Phase 1 Study of ULSC in Patients With Polymyositis (PM) and Dermatomyositis (DM)
|
Early Phase 1 | |
| Completed |
NCT03267277 -
Sodium Thiosulfate for Treatment of Calcinosis Associated With Juvenile and Adult Dermatomyositis
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05437263 -
A Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Dermatomyositis
|
Phase 3 | |
| Active, not recruiting |
NCT04044690 -
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Adults With Dermatomyositis (DM)
|
Phase 3 | |
| Recruiting |
NCT05523167 -
A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.
|
Phase 2/Phase 3 | |
| Not yet recruiting |
NCT06004817 -
Evaluation of Severity in Juvenile and Adult-onset Dermatomyositis
|
||
| Recruiting |
NCT03324152 -
Effects of High-intensity Interval Training (HIIT) in Recent Onset Polymyositis and Dermatomyositis
|
N/A | |
| Completed |
NCT02043548 -
Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis
|
Phase 2 | |
| Completed |
NCT03414086 -
Predictor of Clinical Response to Acthar in Myositis
|
||
| Completed |
NCT04628936 -
Open-label Extension to the Phase 2 Crossover Study (PRESIDIO) Evaluating KZR-616 in Patients With PM and DM.
|
Phase 2 | |
| Recruiting |
NCT03293615 -
Exercise Capacity of Patients With Dermatomyosis
|
N/A |